Singapore, 15 Jan 2025 — Aevice Health, a Singapore-based medtech company specializing in advanced respiratory health solutions, has secured an additional investment from Denka Co., Ltd., a global chemical company, through Pegasus Tech Ventures, along with Singapore-based Deep Tech venture capital firm Elev8.vc.

The funding will accelerate the development and global rollout of Aevice Health’s innovation respiratory health monitoring solutions.

“We are thrilled to welcome Denka Co., Ltd. and Elev8.vc as our new partners. This investment represents a significant milestone for Aevice Health, and we look forward to collaborating closely with Denka and Elev8 to advance our technology and unlock greater value to healthcare professionals and patients” said Adrian Ang, CEO of Aevice Health.

“Through this investment, Denka aims to deepen our initiatives in the healthcare field, with a particular focus on prevention, diagnosis, and treatment”, said Hideki Toya, Managing Executive Officer of Denka Co., Ltd. “By integrating Aevice Health's AI-powered electronic stethoscope technology with our expertise in respiratory infectious diseases and immunology, we strive to further advance our efforts in digital health and address medical challenges. Additionally, Denka will engage in joint research and development of new AI technologies in the field of respiratory diseases and related disease areas.”

“Aevice Health exemplifies how cutting-edge technology can redefine chronic disease management,” said Aditya Mathur, MD of Elev8.vc. “Their approach not only addresses an urgent need for better respiratory care but also demonstrates how remote monitoring can reshape the patient-clinician relationship. We are excited to support their vision of making personalized, data-driven healthcare more accessible and impactful across global markets.”

Driving Innovation in Respiratory Health

Founded in 2018, Aevice Health has emerged as one of the leading players in respiratory health management with its flagship product, the AeviceMD, which has received regulatory approval in both Singapore and the United States. This smart wearable stethoscope provides remote home monitoring of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). By delivering actionable insights, it empowers both patients and clinicians to manage respiratory health more effectively.

The additional funding will enable Aevice Health to expand its market presence, strengthen its research and development efforts, and foster strategic partnerships with healthcare providers worldwide.

About Aevice Health

Aevice Health is a digital health company dedicated to improving asthma and COPD care through its proprietary, non-invasive remote patient monitoring platform and wearable stethoscope, the AeviceMD. Its cutting-edge technology allows for continuous monitoring and real-time disease deterioration tracking, enabling patients to receive personalized care from the comfort of their homes. With actionable insights and effortless treatment response monitoring, healthcare professionals can make timely adjustments for optimized patient outcomes. Aevice Health is on a mission to improve healthcare accessibility, empower patients, and reduce healthcare costs.

More information about the company can be found at www.aevice.com.

‍

About Denka Company Limited

Denka Company Limited, founded in 1915, is a leading chemical manufacturer headquartered in Tokyo, Japan. With a commitment to innovation, sustainability, and technological excellence, Denka operates across diverse sectors including healthcare, infrastructure, electronics, and environmental solutions. The company specializes in advanced materials, functional resins, elastomers, and life sciences products, leveraging its expertise to address global challenges and enhance quality of life.

For more information, visit www.denka.co.jp.

‍

About Elev8.vc‍

Elev8.vc is Singapore’s leading early stage deep-tech VC. The fund invests in and supports promising early-stage companies who develop innovative breakthroughs in technologies or engineering. Elev8.vc companies have ambitious goals to redefine how business gets done. Elev8.vc primarily invests in Smart Mobility, Medtech, Novel Materials, and Complex Computing. As a high-conviction, high-support fund, the team at Elev8.vc looks to continue supporting the audacious founders that are leading the change in these enterprise sectors.

More information is available at https://elev8.vc/.

‍

For media enquiries, please contact:
Daylea Liu
Aevice Health Pte Ltd
Email: hello@aevice.com